2008 | 2007 | 2006 | 2005 | 2004 | 2003
|
| November 9, 2006 |
 Vasogen Raises US$20.3 Million Through Sale of Common Shares and Warrants |
 |
| November 1, 2006 |
| Vasogen to Present at Rodman & Renshaw Healthcare Conference |
|
| October 25, 2006 |
| Vasogen’s ACCLAIM Trial of Celacade™ in Heart Failure Presented at the Canadian Cardiovascular Congress |
|
| October 23, 2006 |
| Vasogen’s Dr. Eldon Smith to Head National Committee on Heart Health |
|
| October 12, 2006 |
| Vasogen to Present at Bio InvestorForum 2006 in San Francisco |
|
| October 12, 2006 |
| Vasogen Announces Third Quarter 2006 Results |
|
| October 5, 2006 |
| Vasogen to Conduct Quarterly Conference Call |
|
| September 13, 2006 |
| Vasogen’s Celacade™ Shown to Significantly Reduce Time in Hospital in Prime Heart Failure Target Population |
|
| September 12, 2006 |
| Vasogen to Present at the A.G. Edwards' Emerging Growth Conference |
|
| September 3, 2006 |
| New Data from Vasogen’s ACCLAIM Trial in Heart Failure Presented at World Congress of Cardiology 2006 |
|
| August 29, 2006 |
| Vasogen to Host Conference Call and Web Cast to Review New ACCLAIM Data Being Presented at the World Congress of Cardiology 2006 |
|
| August 11, 2006 |
| Vasogen Receives NASDAQ Notification Related to Minimum Bid Price |
|
| August 11, 2006 |
| Vasogen Files Amended and Restated Prospectus |
|
| August 2, 2006 |
| Vasogen to Present at the Canaccord Adams 26th Annual Summer Seminar |
|
| July 12, 2006 |
| Vasogen Announces Second Quarter 2006 Results |
|
| July 6, 2006 |
| Vasogen to Conduct Quarterly Conference Call |
|
| June 29, 2006 |
| Vasogen’s ACCLAIM Results to be Presented at the Heart Failure Society of America Meeting in September |
|
| June 26, 2006 |
| Vasogen to Host Conference Call to Discuss Phase III ACCLAIM Results |
|
| June 26, 2006 |
| Vasogen Announces Initial Results from Phase III ACCLAIM Trial in Chronic Heart Failure |
|
| June 14, 2006 |
| Vasogen’s Phase III ACCLAIM Results to be Presented at the World Congress of Cardiology 2006 |
|
| June 7, 2006 |
| Vasogen to Present at Needham & Company Biotechnology and Medical Technology Conference |
|
| May 2, 2006 |
| Preclinical Findings of Vasogen’s VP025 in Model of Diabetic Retinopathy Presented at the 2006 ARVO Conference |
|
| April 17, 2006 |
| Vasogen Announces First Quarter 2006 Results |
|
| April 11, 2006 |
| Vasogen to Conduct Quarterly Conference Call |
|
| March 16, 2006 |
| Vasogen to Conduct Webcast and Conference Call of Annual Meeting |
|
| March 12, 2006 |
| Vasogen Announces Results from Phase III SIMPADICO Trial in Peripheral Arterial Disease |
|
| March 10, 2006 |
| Vasogen to Host Conference Call to Discuss Pivotal Phase III SIMPADICO Results |
|
| February 21, 2006 |
| Vasogen Announces Plans for Terrance H. Gregg to Succeed William R. Grant as Chairman |
|
| February 14, 2006 |
| Vasogen Announces 2005 Year-End Results |
|
| February 7, 2006 |
| Vasogen to Conduct Year-end Conference Call |
|
| February 7, 2006 |
| Vasogen to Present at BIO CEO & Investor Conference |
|
| February 1, 2006 |
| Vasogen’s Phase III SIMPADICO Results to be Presented at Late-Breaking Session of the 55th Annual Scientific Session of the American College of Cardiology |
|
| January 10, 2006 |
| Vasogen Announces the Appointments of Dr. Ronald Cresswell and Dr. Calvin Stiller to Board of Directors |
|
| January 4, 2006 |
| Vasogen Announces Database Lock for Pivotal Phase III SIMPADICO Trial in Peripheral Arterial Disease |
|
Home 
Contact Us 
Search 
Site Map 
Printable Page